Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M. Kawabata R, et al. Among authors: manaka d. Target Oncol. 2023 May;18(3):359-368. doi: 10.1007/s11523-023-00961-x. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060430 Clinical Trial.
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Gastric Cancer. 2018 May;21(3):421-427. doi: 10.1007/s10120-017-0766-x. Epub 2017 Sep 21. Gastric Cancer. 2018. PMID: 28936560 Free PMC article. Clinical Trial.
Correction to: Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC‑06).
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Gastric Cancer. 2018 May;21(3):428. doi: 10.1007/s10120-017-0784-8. Gastric Cancer. 2018. PMID: 29234896 Free PMC article.
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.
Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M. Kotaka M, et al. Among authors: manaka d. ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018. ESMO Open. 2018. PMID: 29713499 Free PMC article.
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y. Oki E, et al. Among authors: manaka d. Br J Cancer. 2019 Jul;121(3):222-229. doi: 10.1038/s41416-019-0518-2. Epub 2019 Jul 9. Br J Cancer. 2019. PMID: 31285591 Free PMC article. Clinical Trial.
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M. Yoshino T, et al. Among authors: manaka d. JAMA Oncol. 2019 Nov 1;5(11):1574-1581. doi: 10.1001/jamaoncol.2019.2572. JAMA Oncol. 2019. PMID: 31513248 Free PMC article. Clinical Trial.
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
Masuishi T, Tsuji A, Kotaka M, Nakamura M, Kochi M, Takagane A, Shimada K, Denda T, Segawa Y, Tanioka H, Hara H, Sagawa T, Watanabe T, Takahashi T, Negoro Y, Manaka D, Fujita H, Suto T, Takeuchi M, Ichikawa W, Fujii M. Masuishi T, et al. Among authors: manaka d. Br J Cancer. 2020 Nov;123(10):1490-1495. doi: 10.1038/s41416-020-01042-w. Epub 2020 Aug 31. Br J Cancer. 2020. PMID: 32863385 Free PMC article. Clinical Trial.
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y. Takahashi T, et al. Among authors: manaka d. ESMO Open. 2021 Apr;6(2):100093. doi: 10.1016/j.esmoop.2021.100093. Epub 2021 Mar 19. ESMO Open. 2021. PMID: 33744811 Free PMC article. Clinical Trial.
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.
Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, Takeuchi M, Ichikawa W, Fujii M. Tsuji A, et al. Among authors: manaka d. Target Oncol. 2021 Nov;16(6):753-760. doi: 10.1007/s11523-021-00845-y. Epub 2021 Oct 31. Target Oncol. 2021. PMID: 34718946 Review.
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Sakamoto Y, Shiozawa M, Nishi M, Horiuchi T, Yamagishi H, Sakamoto J, Mizushima T, Ohtsu A, Mori M. Yoshino T, et al. Among authors: manaka d. J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5. J Clin Oncol. 2022. PMID: 35512259 Clinical Trial.
63 results